ALZHEIMER DISEASE IN 2016: Putting AD treatments and biomarkers to the test

    loading  Checking for direct PDF access through Ovid

Abstract

Investigational treatments to impede the progression of Alzheimer disease (AD) are being evaluated in clinical trials, and biomarkers to detect and track the disease are being developed and deployed. Recent findings underscore the importance of ongoing clinical trials and biomarker developments in the understanding, treatment and prevention of AD.

Related Topics

    loading  Loading Related Articles